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Background: Hematolymphoid neoplasms frequently harbor recurrent genetic abnormalities. Some of the most
well recognized lesions are chromosomal translocations, and many of these are known to play pivotal roles in
pathogenesis. In lymphoid malignancies, some translocations result from erroneous V(D)J-type events. However,
other translocation junctions appear randomly positioned and their underlying mechanisms are not understood.
Results: We tested the hypothesis that genomic repeats, including both simple tandem and interspersed repeats,
are involved in chromosomal translocations arising in hematopoietic malignancies. Using a database of
translocation junctions and RepeatMasker annotations of the reference genome assembly, we measured the
proximity of translocation sites to their nearest repeat. We examined 1,174 translocation breakpoints from 10
classifications of hematolymphoid neoplasms. We measured significance using Student’s t-test, and we determined
a false discovery rate using a random permutation statistics technique.
Conclusions: Most translocations showed no propensity to involve genomic repeats. However, translocation
junctions at the transcription factor 3 (TCF3)/E2A immunoglobulin enhancer binding factors E12/E47 (E2A) locus
clustered within, or in proximity to, transposable element sequences. Nearly half of reported TCF3 translocations
involve a MER20 DNA transposon. Based on this observation, we propose this sequence is important for the
oncogenesis of TCF3-PBX1 acute lymphoblastic leukemia.Background
Genomic rearrangements can occur in germline nuclei,
resulting in inherited diseases, or in somatic nuclei, con-
tributing to tumorigenesis. The latter can vary from com-
plex events such as chromothripsis, to relatively simple
abnormalities such as recurrent chromosomal transloca-
tions; the underlying mechanisms remain unclear. Gen-
omic rearrangements have been induced in mammalian
cell cultures in few systems [1-3]. Although these in vitro
generated translocations provide a valuable experimental
tool, the engineered translocation partner sequences rarely
match known oncogenic translocation sequences [4].
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reproduction in any medium, provided the orWidely used assays include karyotyping, fluorescence in
situ hybridizations, and microarray platforms with probes
for comparative genomic hybridization and single nucleo-
tide polymorphism genotyping. None provides nucleotide
resolution of translocation breakpoints; massively parallel
short-read sequencing has this ability, particularly when
tailored approaches are used to ‘rescue’ alignments of reads
spanning the breakpoints. However, highly repetitive inter-
vals at breakpoints may be a confounding factor.
Breakpoints resolved precisely can provide insights
into the mechanisms responsible for rearrangements. For
example, some hematolymphoid neoplasm breakpoints are
marked by the presence of cryptic heptamer/nanomer se-
quences [5]. Similarly, Translin protein binding sequences
have been detected near chromosomal breakpoints in
lymphoid neoplasms [6]. In both scenarios, DNA sequence
is a key participant in the mechanism of translocation.
We chose to look for evidence of genomic repeat
involvement in chromosomal translocations that drivetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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comprise nearly half of the human genome; many are in-
terspersed repeats reflecting insertions of mobile DNA
sequences [7]. Because of their prevalence in genomes,
these repeats are intrinsic substrates for homologous re-
combination and single strand annealing reactions [8,9].
For unknown reasons, repeating elements are also dis-
proportionately involved in non-homologous end joining
events at specific loci. One example of this occurs in a
mouse model of MYC-induced lymphoma, which shows
increased LINE-1 retrotransposon sequences at break
sites with no homology or short microhomologies (1–4 bp)
suggestive of non-homologous end joining [10].
To address the question, we took advantage of two re-
sources, the RepeatMasker annotation of the reference
human genome assembly [http://www.repeatmasker.org],
and a compilation of more than 1,000 chromosomal trans-
location spanning sequences curated by the Liber labora-
tory [11]. For each translocation junction, we measured
distance to the nearest repeat. To avoid erroneous associa-
tions between translocation junctions and repeats, we
compared randomly permuted positions within the trans-
location gene locus.
Results and discussion
Translocation junctions from ten types of hematolym-
phoid neoplasm (Table 1) were analyzed to determine
whether these occurred within or closer to the nearest
repeat than would be expected by chance (Figure 1). The
percent of translocation junctions occurring within re-
peat intervals varied, partly as a reflection of repeatTable 1 Translocation regions studied












TCF3: transcription factor 3; PBX1: pre B-cell leukemia transcription factor 1; BCR: break
MLL: myeloid/lymphoid or mixed lineage leukemia gene; ETV6: ets variant gene 6; RUN
translocated to, 1; MYC: v-myc avian myelocytomatosis viral oncogene homolog; IGH: Ig
hematopoietic transcription factor; TCRA: T-cell antigen receptor, alpha subunit; LMO2:
*Distinct hematolymphoid neoplasms according to the World Health Organization c
myelogenous leukemia; Therapy AML: therapy-related acute myeloid leukemia; spo
‡Number of translocation junctions examined.content at the involved gene loci. For example, 67% of
translocation junctions in both transcription factor 3/
transcription factor E2-alpha (TCF3) and abelson murine
leukemia viral oncogene homolog 1 (ABL1) were present
in repeats (Table 2). In contrast, only 2–3% of junctions
in runt-related transcription factor 1; translocated to,
1 (RUNX1T1) were in repeats (Table 2). The longest
average and shortest average observed distances between
translocations and their nearest repeat were 684 bp and
1 bp in T-cell receptor alpha chain (TCRA) and TCF3,
respectively (Table 2).
Next, we calculated ratios of the expected versus ob-
served translocation-to-repeat distances (Figure 2). The
largest ratio, reflecting a relative enrichment of transloca-
tion junctions in the vicinity of repeats, occurred in the
TCF3 translocation junction region (TCF locus ratio = 42,
average ratio for other loci = 1.15) (Figure 2). Applying
permutation based statistics, as described in the Methods
section, confirmed significance of the enrichment of
TCF3 translocation junction at genomic repeats (n = 30;
P <0.001) (Table 2). Using the same approach, we note a
weaker association between translocations and genomic
repeats at the ABL1 region (n = 27; P = 0.017) (Table 2).
The TCF3 translocation junction region encompasses
interspersed repeats from three categories, including a
small nuclear RNA sequence (U6 snRNA), five retro-
transposons, and a hAT-Charlie family DNA transposon
(MER20). The retrotransposons at the locus include two
Short INterspersed Elements (SINE) elements (AluY and
AluJb), and three Long INterspersed Elements (LINE)
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Figure 1 Experimental outline depicting a hypothetical translocation region encompassing three translocation junctions. An illustration
on the left represents the hypothesis, where there is a spatial association (symbol X) between the three observed translocation junctions (red triangles)
and the nearest repeated sequence (blue arrow). Similarly, an illustration on the right represents the null hypothesis, where there is no spatial association
(symbol X’) between three randomly generated translocation junctions (broken triangles) and their nearest repeat (blue arrow). We compared actual
translocation junctions to 1,000 randomly generated positions to identify translocation junction regions that consistently happen near repeats.
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reside in the MER20 transposon (Figure 3); the distribu-
tion of MER20 embedded translocation junctions was
non-random (Figure 3, inset).
Recurrent pathologic translocations occur in a wide
range of human malignancies, from hematolymphoid
cancers to carcinomas and sarcomas. As the genetics of
these diseases are better characterized, specific lesions
are being related to clinicopathological entities or even
incorporated in their definition [12]. Sequence features
at breakpoints can lend insights into how these events
occur, and so we decided to investigate the prevalence of
breakpoints with respect to genomic repeats. There have
been other reports of non-uniform distributions of
transposable element sequences at sites of chromosomal
breaks. For example, nucleotide junctions demarking the
postnatal chromosome 12p deletions in ETV6-RUNX1
leukemia often occur at, or near, retrotransposon se-
quences [13].
In our study, we looked at rearrangement sites at 20
gene loci. Only TCF3 translocation sites exhibited cluster-
ing at or near transposable element sequences. All other
translocation junctions from malignant proliferations of
lymphoid and myeloid lineages showed random distribu-
tions relative to nearby repeats.
Our study leaves the mechanism unaddressed. How
could TCF3 repeats create a site susceptible to breakage
or otherwise involve the locus in events leading to the
translocation? It is possible that very short sequences also
occurring randomly are sufficient. Prior work by Tsai et al.has shown that dsDNA breaks at the TCF3/E2A locus
leading to translocations occurring in clusters at CpG
dinucleotides [11]. This is similar to some other hotspots
for breaks occurring the pro-B/pre-B stage of B-cell mat-
uration. Of note, though, CpG nucleotides are not at break
sites seen in the TCF3 fusion partner locus, pre-B-cell
leukemia homeobox 1 (PBX1). CpG dinucleotides oc-
curred on 53% of TCF3 translocation junctions, while
transposable elements were found on 67% of TCF3 trans-
location sites.
It is also possible that a lengthier protein recognition
sequence is important near the break site. Transposable
elements can contain, for example, transcription factor
binding sites and other regulatory protein binding
sites important for transcriptional control around the re-
peat [14,15]. Indeed, MER20 DNA transposons provide
cis-regulatory sequences critical for inducing the tran-
scription of prolactin during pregnancy and have been
implicated in endometrial gene recruitment in the evolu-
tion of placental mammals [14,16,17].Conclusions
In summary, we analyzed 1,174 translocation sequences
from ten hematolymphoid neoplasms for proximity to
nearby repeats. Of these, TCF3 translocation junctions
were seen to cluster at or near transposable elements in a
majority of TCF3-PBX1 acute lymphoblastic leukemia. It is
possible that the involved transposable element sequences
are inherently susceptible to dsDNA breaks. Further
Table 2 Repeat features at the translocation regions studied
Translocation junction regions Junctions occurring in repeats (%) Junction to the nearest repeat‡ (bp) P value for interaction
E2A = PBX1 (TCF3-PBX1) Observed Expected
TCF3 20 (67) 1 42.46 <0.001†/<0.001*
PBX1 1 (3) 384.2 272.24 0.999
BCR-ABL
BCR 14 (35) 293.5 251.37 0.978
ABL 18 (67) 37.74 171.48 0.017†/0.449*
Therapy-related MLLs
t-MLL 2 (15.4) 34.54 95.38 0.373
t-MLLT3 3 (23) 242.85 264.64 0.949
MLLs rearranged
MLL 72 (35.3) 156 108.78 0.999
AFF1 46 (21.1) 208.31 144.39 0.999
MLL 6 (50) 50.34 82.35 0.798
MLLT3 2 (16.7) 209.1 289.9 0.831
ETV6-RUNX1
ETV6 15 (29) 121.11 113.64 0.987
RUNX1 6 (11) 284.54 245.3 0.966
RUNX1-RUNX1TL
RUNX1 18 (27) 236.48 243.63 0.949
RUNX1TL 3 (2) 494.21 264.41 0.999
MYC-IGH
MYC 8 (6) 399.1 116.44 0.999
IGH 29 (63) 668.86 298.77 0.999
BCL6-IGH
BCL6 2 (5) 151.81 174.16 0.763
IGH 9 (64) 124.86 190.5 0.978
SCL-TCRA
SCL 1 (6) 284.43 192.11 0.998
TCRA 5 (16) 648.96 396.16 0.999
LMO2-TCRA
LMO2 5 (17) 160.86 208.56 0.704
TCRA 3 (10) 545.1 194.47 1
‡Distance, expressed in number of nucleotides, from translocation junction to the nearest repeat.
†P value for interaction between translocation junction to the nearest repeat (including repeating elements and tandem repeats).
*P value for interaction between translocation junction to the nearest repeating element.
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for TCF3-PBX1 and other leukemogenic translocations.
Methods
Translocation junction sequences
Genomic DNA from human clinical samples was ex-
tracted and translocations were Sanger sequenced by
numerous independent investigators [11]. Published se-
quences assembled by Tsai et al. are publically accessible
in a repository, herein referred to as the Lieber database
(http://lieber.usc.edu/Data.aspx) [11]. The Lieber databaseincludes translocation junction sequences, translocation
genomic coordinates (hg18), and limited clinical data from
various hematolymphoid neoplasms that are associated
with recurrent translocations. We downloaded this infor-
mation (Table 1), and analyzed loci with ten or more
translocation breakpoints (Additional file 1).
Mapping breakpoints with respect to repeats
Distances between each translocation junction and its
nearest repeat element were determined by a Perl script
























Figure 2 Translocation junctions in TCF3 occur at or near repeats. The Y-axis denotes the expected versus observed ratio of distances
between translocation junctions and their nearest repeats. The X-axis denotes translocation loci analyzed. Other translocations examined were
independent of local repeat content; expected versus observed ratios for these loci approach one (1). See Table 1 for abbreviations.
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GRCh36/hg18 assembly version of the human genome.
Translocation was annotated for repetitive sequences
using Tandem Repeat Finder and RepeatMasker. We in-
cluded the two major categories of genomic repeats: tan-
dem repeats and interspersed repeats. The number of
nucleotides between the translocation and its nearest re-
peat were then calculated, considering upstream and
downstream sequences. For each locus, the observed1568910 1568920
1566000 1567000 1568000




Figure 3 Schematic representation of a TCF3 locus including transloc
individual translocation junctions, the blue arrows indicate transposable ele
TCF3 translocation junction density map within the MER20 transposon. Gen
genome assembly. TCF3: Transcription factor 3; MER20: Medium reiteration
Long INterspersed Element 2; Alu: Alu SINE; U6: Small nuclear RNA.distribution of distances was compared to distances found
using random positions as substitutes for translocation
junction (Figure 1).
Statistical methods
For each of the twenty translocation intervals analyzed, we
compared actual measurements between translocation
junction and their nearest genomic repeats against the
distances separating 1,000 random positions and their1568930 1568940
1569000 1570000 1571000
slocation junction region (Chr19)
MER20 L2
ations and transposable elements. The red triangles represent
ments within TCF3, and the black rectangles identify TCF3 exons. Inset,
ome coordinates correspond to March 2006, NCBI36/hg18 human
frequency repetitive 20; L1: LINE-1 Long INterspersed Element 1; L2:
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lated a Student’s t-value and its P value. For each of the
twenty translocation intervals analyzed, we compared ac-
tual measurements between translocation junction and
their nearest genomic repeats to the distances separating
1,000 random positions and their corresponding nearest
repeats. Each translocation was compared to the distribu-
tion of distances created by the random sites using a one-
sided Student’s t-test, to generate a P value; low P values
indicate that the translocation is significantly closer to a
repeat element than expected by random chance.
Additional files
Additional file 1: Nucleotide positions of translocation junctions
examined. Column A depicts a gene symbol that specifies one of the
two translocation partners within a given hematolymphoid neoplasm
with recurrent genetic abnormality. Column B denotes sequence used to
determine translocation junction. Columns C and D denote chromosomal
position and nucleotide position of translocation junction, relative to
March 2006 Human Genome Assembly (hg18).
Additional file 2: Program used to calculate translocation junction
to repeat distance and to generate 1,000 random positions for each
translocation region.
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